IMNN — Imunon, Inc.
$1.23-0.40%
Last close: · regular session
Last 60 sessions
IMNN closed at $1.23 (-0.40%) on Oct 26, 2026. Recent offering filing (S-1, Oct 2026). Float: 5.4M shares. Latest SEC filing: 8-K on Oct 27, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for IMNN in the TickerWise workspace.
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 25
- Website: https://www.imunon.com
Latest SEC filings for IMNN
Latest IMNN news
- IMUNON to Participate in Upcoming Investor Conferences Read article
- IMUNON Converts $1.2 Million of Debt-to-Equity Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.